[go: up one dir, main page]

RS50641B - Vodeni farmaceutski preparat koji sadrži roflumilast - Google Patents

Vodeni farmaceutski preparat koji sadrži roflumilast

Info

Publication number
RS50641B
RS50641B RSP-2008/0591A RSP20080591A RS50641B RS 50641 B RS50641 B RS 50641B RS P20080591 A RSP20080591 A RS P20080591A RS 50641 B RS50641 B RS 50641B
Authority
RS
Serbia
Prior art keywords
pharmaceutical preparation
preparation according
roflumilast
solution
polyethylene glycol
Prior art date
Application number
RSP-2008/0591A
Other languages
English (en)
Serbian (sr)
Inventor
Rudolf Linder
Original Assignee
Nycomed Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh. filed Critical Nycomed Gmbh.
Publication of RS50641B publication Critical patent/RS50641B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Farming Of Fish And Shellfish (AREA)
RSP-2008/0591A 2004-09-22 2005-09-21 Vodeni farmaceutski preparat koji sadrži roflumilast RS50641B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004046235A DE102004046235A1 (de) 2004-09-22 2004-09-22 Arzneimittelzubereitung
PCT/EP2005/054723 WO2006032675A1 (fr) 2004-09-22 2005-09-21 Préparation pharmaceutique aqueuse comprenant du roflumilast

Publications (1)

Publication Number Publication Date
RS50641B true RS50641B (sr) 2010-06-30

Family

ID=35447576

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0591A RS50641B (sr) 2004-09-22 2005-09-21 Vodeni farmaceutski preparat koji sadrži roflumilast

Country Status (17)

Country Link
US (1) US9205044B2 (fr)
EP (1) EP1796668B1 (fr)
JP (1) JP5044404B2 (fr)
AT (1) ATE408405T1 (fr)
AU (1) AU2005286476B2 (fr)
CA (1) CA2580397C (fr)
CY (1) CY1109407T1 (fr)
DE (2) DE102004046235A1 (fr)
DK (1) DK1796668T3 (fr)
ES (1) ES2314718T3 (fr)
HR (1) HRP20080640T3 (fr)
ME (1) ME01050B (fr)
PL (1) PL1796668T3 (fr)
PT (1) PT1796668E (fr)
RS (1) RS50641B (fr)
SI (1) SI1796668T1 (fr)
WO (1) WO2006032675A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US8795634B2 (en) * 2008-09-12 2014-08-05 Critical Pharmaceuticals Limited Absorption of therapeutic agents across mucosal membranes or the skin
WO2010132507A2 (fr) 2009-05-11 2010-11-18 Cytotech Labs, Llc Méthodes de traitement de maladie à l'aide d'un décaleur épimétabolique (coenzyme q10)
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
NZ720022A (en) 2010-03-12 2018-07-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
EP3320902B1 (fr) * 2011-03-07 2021-02-17 Amgen (Europe) GmbH Procédés de traitement de maladies à l'aide de composés isoindolines
ES2762451T3 (es) 2011-04-04 2020-05-25 Berg Llc Tratamiento de tumores del sistema nervioso central con coenzima Q10
CN102793684B (zh) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 罗氟司特液体制剂及其制备方法
MY183615A (en) 2011-06-17 2021-03-03 Berg Llc Inhalable pharmaceutical compositions
WO2014012954A1 (fr) 2012-07-18 2014-01-23 Takeda Gmbh Traitement de l'asthme sévère partiellement régulé ou non régulé
EP2983654B1 (fr) 2013-04-08 2025-11-12 BPGbio, Inc. Traitement du cancer à l'aide de polythérapies par coenzyme q10
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
AU2014315186B2 (en) 2013-09-04 2020-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
CN105287366B (zh) * 2014-06-18 2018-02-16 张蕊 一种维生素k1注射液及其制备方法
CN106573889B (zh) 2014-10-24 2019-01-01 久光制药株式会社 前药
WO2017007957A1 (fr) * 2015-07-07 2017-01-12 Mast Therapeutics, Inc. Formulations de poloxamère-188 à teneur en sodium réduite et procédés d'utilisation
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
KR20210044191A (ko) 2018-06-04 2021-04-22 아큐티스, 인크. 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
KR102117525B1 (ko) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
CA3166300A1 (fr) 2020-01-31 2021-08-05 David W. Osborne Formulation de roflumilast topique ayant une administration et une demi-vie plasmatique ameliorees
CN115666652A (zh) * 2020-02-03 2023-01-31 千寿制药株式会社 聚醚系化合物的用途
MX2023006602A (es) 2020-12-04 2023-08-07 Arcutis Biotherapeutics Inc Formulación tópica de roflumilast que tiene propiedades antimicoticas.
WO2022169615A1 (fr) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Formulations de roflumilast à profil pharmacocinétique amélioré
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
IL304924A (en) 2021-02-10 2023-10-01 Iolyx Therapeutics Inc Methods for ophthalmic delivery of roflumilast
MX2024003580A (es) 2021-09-22 2024-04-05 Iolyx Therapeutics Inc Metodos de tratamiento de enfermedades inflamatorias oculares.
IL313866A (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics Inc Topical roflomilest spray foams
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2165192C (fr) 1993-07-02 2001-04-24 Hermann Amschler Derives de substitution fluoroalcoxy de benzamides et leur utilisation comme inhibiteurs de la nucleotide phosphodiesterase cyclique
AU755445B2 (en) * 1998-05-07 2002-12-12 Corixa Corporation Adjuvant composition and methods for its use
EP1161239B1 (fr) 1999-03-10 2004-10-20 ALTANA Pharma AG 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide pour le traitement de la sclerose en plaques
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ATE485821T1 (de) * 2002-05-28 2010-11-15 Nycomed Gmbh Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen
US20030235631A1 (en) * 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
PL213925B1 (pl) * 2002-07-19 2013-05-31 Abbott Biotech Ltd Przeciwcialo anty-TNFα lub jego czesc wiazaca antygen, ich zastosowanie oraz zestaw

Also Published As

Publication number Publication date
DE102004046235A1 (de) 2006-03-30
DE602005009848D1 (de) 2008-10-30
EP1796668B1 (fr) 2008-09-17
JP2008513416A (ja) 2008-05-01
US20070259009A1 (en) 2007-11-08
PT1796668E (pt) 2008-12-22
AU2005286476A1 (en) 2006-03-30
US9205044B2 (en) 2015-12-08
HRP20080640T3 (en) 2009-01-31
SI1796668T1 (sl) 2009-02-28
CA2580397C (fr) 2013-07-30
DK1796668T3 (da) 2009-02-02
ME01050B (me) 2012-10-20
EP1796668A1 (fr) 2007-06-20
JP5044404B2 (ja) 2012-10-10
CA2580397A1 (fr) 2006-03-30
CY1109407T1 (el) 2014-07-02
ATE408405T1 (de) 2008-10-15
AU2005286476B2 (en) 2011-11-10
WO2006032675A1 (fr) 2006-03-30
ES2314718T3 (es) 2009-03-16
PL1796668T3 (pl) 2009-02-27

Similar Documents

Publication Publication Date Title
RS50641B (sr) Vodeni farmaceutski preparat koji sadrži roflumilast
US20210116207A1 (en) Topically applicable pharmaceutical preparation
CN109475537A (zh) 治疗肝纤维化的方法
US10888552B2 (en) Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
US20080045572A1 (en) Pharmaceutical Composition Comprising Roflumilast or the N-Oxide of Roflumilast
JP2014185161A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
JP2018535249A (ja) ランピルナーゼおよび／またはアンフィナーゼを使用するウイルス性結膜炎の処置
JPH11228448A (ja) 非ステロイド系抗炎症薬の非経口で水混和性の非濃色注射可能組成物
JP5434981B2 (ja) 点眼剤
WO2021205341A1 (fr) 1-méthylnicotinamide destiné à la prévention/le traitement de maladies inflammatoires des voies respiratoires
JP4961671B2 (ja) 点眼剤
WO2024224326A1 (fr) Formulations parentérales liquides de bilastine
WO2024224308A1 (fr) Formulations parentérales liquides de bilastine exemptes de cyclodextrines
JP2001335467A (ja) 非ステロイド系抗炎症薬の非経口で水混和性の非濃色注射可能組成物